Avidity Biosciences, Inc.
- Jurisdiction
United States - ISIN
US05370A1088 (RNA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. Read full profile
Fundamentals
- Net revenue
€9.15M - Gross margin
92.4% - EBIT
-€445.06M - EBIT margin
-4,863.3% - Net income
-€388.73M - Net margin
-4,247.8%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
|
|
|
|
| Mosbrooker Eric | Chief Commercial Officer |
|
|
|
|
| Elkins David V | EVP, Chief Financial Officer |
|
|
|
|
| Gallagher Kathleen P. | Chief Program Officer |
|
|
|
|
| Boyce Sarah | President and CEO |
|
|
|
|
Earnings Calls
Earnings Calls
Latest earnings call: November 17, 2014 (Q3 2014)